Skip to content

Clinical trials

Diabetes Mellitus, Type 1 trials in Spain

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 1 Country / region: Spain Clear all

145 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20025
20052
20064
20071
20084
20095
20104
20113
20122
20134
20148
20156
20162
201713
20185
20198
20203
202110
20227
20238
202411
202517
202611

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed96
Recruiting16
Unknown status11
Terminated9
Not yet recruiting6
Active, not recruiting5
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S12
Castilla-La Mancha Health Service11
Eli Lilly and Company11
Sanofi7
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal6
University of Valencia6
Hospital Clinic of Barcelona5
Medtronic MiniMed, Inc.5
Adhera Health, Inc.4
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 1145
Diabetes Mellitus23
Diabetes Mellitus, Type 212
Insulin Resistance9
Asthma4
Obesity4
Overweight4
Autoimmune Diseases3
Cardiovascular Diseases3
Hypoglycemia3

Trials

Showing 1 to 25 of 145. Each trial links to its page on Pharma Observatory.

45 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.